Literature DB >> 33187459

Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.

Betsy Ann Joseph1, Mahmoud Dibas2, Kirk W Evanson3, Geeta Paranjape3, Charan Thej Reddy Vegivinti4, Pragadeesh Thamarai Selvan4, Kavitha Saravu5, Nitin Gupta5, Yashwitha Sai Pulakurthi6, Praneeth Reddy Keesari6, Sriram Varsha7, Spandana Chittajallu8, Adam A Dmytriw9, Natalie L Reierson1, Nick Mikoff1, Shelby Kamrowski1, Megan Schmidt1, Amber R Davis3, John M Pederson3, Hemant K Mishra10, Jillienne C Touchette3, Kevin Kallmes1.   

Abstract

Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19.
Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events.
Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment.
Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of COVID-19 patients. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19.

Entities:  

Keywords:  Coronavirus; antiviral agents; lopinavir/ritonavir; pneumonia; sars virus; severe acute respiratory syndrome

Year:  2020        PMID: 33187459     DOI: 10.1080/14787210.2021.1848545

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

Review 1.  Lessons from SARS‑CoV‑2 and its variants (Review).

Authors:  Ziwen Qin; Yan Sun; Jian Zhang; Ling Zhou; Yujuan Chen; Chuanjun Huang
Journal:  Mol Med Rep       Date:  2022-06-22       Impact factor: 3.423

Review 2.  Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.

Authors:  Gokben Sahin; Ozlem Akbal-Dagistan; Meltem Culha; Aybige Erturk; Nur Sena Basarir; Serap Sancar; Ayca Yildiz-Pekoz
Journal:  J Pharm Sci       Date:  2022-06-09       Impact factor: 3.784

3.  Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.

Authors:  Charan Thej Reddy Vegivinti; Kirk W Evanson; Hannah Lyons; Izzet Akosman; Averi Barrett; Nicole Hardy; Bernadette Kane; Praneeth Reddy Keesari; Yashwitha Sai Pulakurthi; Erin Sheffels; Prasanth Balasubramanian; Richa Chibbar; Spandana Chittajallu; Kathryn Cowie; J Karon; Lauren Siegel; Ranita Tarchand; Caleb Zinn; Nitin Gupta; Kevin M Kallmes; Kavitha Saravu; Jillienne Touchette
Journal:  BMC Infect Dis       Date:  2022-01-31       Impact factor: 3.090

Review 4.  Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.

Authors:  Windi Fresha Qomara; Delya Nur Primanissa; Salma Hasni Amalia; Febby V Purwadi; Neily Zakiyah
Journal:  Int J Gen Med       Date:  2021-11-23

5.  Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form.

Authors:  Payam Tabarsi; Hossein Vahidi; Ali Saffaei; Seyed Mohammad Reza Hashemian; Hamidreza Jammati; Bahram Daraei; Arash Mahboubi; Farzad Kobarfard; Majid Marjani; Afshin Moniri; Zahra Abtahian; Atefeh Abedini; Alireza Eslaminejad; Jalal Heshmatnia; Maryam Sadat Mirenayat; Atefeh Fakharian; Sharareh Seifi; Mohsen Sadeghi; Alireza Dastan; Sara Haseli; Seyed Alireza Nadji; Raha Eskandari; Sahar Yousefian; Mohammad Varahram; Alireza Zali; Ali Akbar Velayati; Farzaneh Dastan
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

6.  Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.

Authors:  Mehdi Hassaniazad; Hossein Farshidi; Abdollah Gharibzadeh; Ali Bazram; Elham Khalili; Afsaneh Noormandi; Mohammad Fathalipour
Journal:  J Med Virol       Date:  2022-03-24       Impact factor: 20.693

7.  Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study.

Authors:  Augusto Di Castelnuovo; Simona Costanzo; Andrea Antinori; Nausicaa Berselli; Lorenzo Blandi; Marialaura Bonaccio; Raffaele Bruno; Roberto Cauda; Alessandro Gialluisi; Giovanni Guaraldi; Lorenzo Menicanti; Marco Mennuni; Ilaria My; Agostino Parruti; Giuseppe Patti; Stefano Perlini; Francesca Santilli; Carlo Signorelli; Giulio G Stefanini; Alessandra Vergori; Walter Ageno; Luca Aiello; Piergiuseppe Agostoni; Samir Al Moghazi; Rosa Arboretti; Filippo Aucella; Greta Barbieri; Martina Barchitta; Alessandro Bartoloni; Carolina Bologna; Paolo Bonfanti; Lucia Caiano; Laura Carrozzi; Antonio Cascio; Giacomo Castiglione; Mauro Chiarito; Arturo Ciccullo; Antonella Cingolani; Francesco Cipollone; Claudia Colomba; Crizia Colombo; Francesco Crosta; Giovanni Dalena; Chiara Dal Pra; Gian Battista Danzi; Damiano D'Ardes; Katleen de Gaetano Donati; Francesco Di Gennaro; Giuseppe Di Tano; Gianpiero D'Offizi; Tommaso Filippini; Francesco Maria Fusco; Carlo Gaudiosi; Ivan Gentile; Giancarlo Gini; Elvira Grandone; Gabriella Guarnieri; Gennaro L F Lamanna; Giovanni Larizza; Armando Leone; Veronica Lio; Angela Raffaella Losito; Gloria Maccagni; Stefano Maitan; Sandro Mancarella; Rosa Manuele; Massimo Mapelli; Riccardo Maragna; Lorenzo Marra; Giulio Maresca; Claudia Marotta; Franco Mastroianni; Maria Mazzitelli; Alessandro Mengozzi; Francesco Menichetti; Jovana Milic; Filippo Minutolo; Beatrice Molena; R Mussinelli; Cristina Mussini; Maria Musso; Anna Odone; Marco Olivieri; Emanuela Pasi; Annalisa Perroni; Francesco Petri; Biagio Pinchera; Carlo A Pivato; Venerino Poletti; Claudia Ravaglia; Marco Rossato; Marianna Rossi; Anna Sabena; Francesco Salinaro; Vincenzo Sangiovanni; Carlo Sanrocco; Laura Scorzolini; Raffaella Sgariglia; Paola Giustina Simeone; Michele Spinicci; Enrico Maria Trecarichi; Giovanni Veronesi; Roberto Vettor; Andrea Vianello; Marco Vinceti; Elena Visconti; Laura Vocciante; Raffaele De Caterina; Licia Iacoviello
Journal:  Front Med (Lausanne)       Date:  2021-06-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.